PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline

Roberta Mercorio, Laura Pergoli, Daniela Galimberti, Chiara Favero, Michele Carugno, Elisabetta Dalla Valle, Francesco Barretta, Francesca Cortini, Elio Scarpini, Valentina Bollati Valentina, Angela Cecilia Pesatori

Research output: Contribution to journalArticle

Abstract

Epigenetic mechanisms might be involved in Alzheimer's disease (AD). Genetic polymorphisms in several genes, including APOE (Apolipoprotein E), PSEN1 (Presenilin 1), CR1 (Complement receptor 1), and PICALM (Phosphatidylinositol binding clathrin assembly protein), have been associated to an increased AD risk. However, data regarding methylation of these specific genes are lacking. We evaluated DNA methylation measured by quantitative bisulfite-PCR pyrosequencing in 43 AD patients and 38 healthy subjects (HS). In a multivariate age- and gender-adjusted model, PICALM methylation was decreased in AD compared to HS (mean = 3.54 and 4.63, respectively, p = 0.007). In AD, PICALM methylation level was also positively associated to Mini-Mental Scale Examination (MMSE) score (percent change 3.48%, p = 0.008). Moreover, a negative association between PICALM methylation and age was observed only in HS (percent change - 2.29%, p = 0.002). In conclusion, our data suggest a possible role of PICALM methylation in AD, particularly related to cognitive function. Given the small study sample and the associative nature of our study, further prospective investigations are required to assess the dynamics of DNA methylation in the early stages of AD development.

Original languageEnglish
Pages (from-to)283-292
Number of pages10
JournalJournal of Alzheimer's Disease
Volume65
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Hematologic Diseases
Methylation
Alzheimer Disease
Genes
Healthy Volunteers
DNA Methylation
Vesicular Transport Adaptor Proteins
Complement C1
Presenilin-1
Complement Receptors
Genetic Polymorphisms
Phosphatidylinositols
Cognitive Dysfunction
Epigenomics
Cognition
Carrier Proteins
Prospective Studies
Polymerase Chain Reaction

Keywords

  • Alzheimer's disease
  • epigenetics
  • methylation
  • Mini-Mental State Examination
  • PICALM

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline. / Mercorio, Roberta; Pergoli, Laura; Galimberti, Daniela; Favero, Chiara; Carugno, Michele; Dalla Valle, Elisabetta; Barretta, Francesco; Cortini, Francesca; Scarpini, Elio; Valentina, Valentina Bollati; Pesatori, Angela Cecilia.

In: Journal of Alzheimer's Disease, Vol. 65, No. 1, 01.01.2018, p. 283-292.

Research output: Contribution to journalArticle

Mercorio, Roberta ; Pergoli, Laura ; Galimberti, Daniela ; Favero, Chiara ; Carugno, Michele ; Dalla Valle, Elisabetta ; Barretta, Francesco ; Cortini, Francesca ; Scarpini, Elio ; Valentina, Valentina Bollati ; Pesatori, Angela Cecilia. / PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline. In: Journal of Alzheimer's Disease. 2018 ; Vol. 65, No. 1. pp. 283-292.
@article{10d52d0cfa504b9a874d8b95d3c47e67,
title = "PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline",
abstract = "Epigenetic mechanisms might be involved in Alzheimer's disease (AD). Genetic polymorphisms in several genes, including APOE (Apolipoprotein E), PSEN1 (Presenilin 1), CR1 (Complement receptor 1), and PICALM (Phosphatidylinositol binding clathrin assembly protein), have been associated to an increased AD risk. However, data regarding methylation of these specific genes are lacking. We evaluated DNA methylation measured by quantitative bisulfite-PCR pyrosequencing in 43 AD patients and 38 healthy subjects (HS). In a multivariate age- and gender-adjusted model, PICALM methylation was decreased in AD compared to HS (mean = 3.54 and 4.63, respectively, p = 0.007). In AD, PICALM methylation level was also positively associated to Mini-Mental Scale Examination (MMSE) score (percent change 3.48{\%}, p = 0.008). Moreover, a negative association between PICALM methylation and age was observed only in HS (percent change - 2.29{\%}, p = 0.002). In conclusion, our data suggest a possible role of PICALM methylation in AD, particularly related to cognitive function. Given the small study sample and the associative nature of our study, further prospective investigations are required to assess the dynamics of DNA methylation in the early stages of AD development.",
keywords = "Alzheimer's disease, epigenetics, methylation, Mini-Mental State Examination, PICALM",
author = "Roberta Mercorio and Laura Pergoli and Daniela Galimberti and Chiara Favero and Michele Carugno and {Dalla Valle}, Elisabetta and Francesco Barretta and Francesca Cortini and Elio Scarpini and Valentina, {Valentina Bollati} and Pesatori, {Angela Cecilia}",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-180242",
language = "English",
volume = "65",
pages = "283--292",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - PICALM gene methylation in blood of Alzheimer's disease patients is associated with cognitive decline

AU - Mercorio, Roberta

AU - Pergoli, Laura

AU - Galimberti, Daniela

AU - Favero, Chiara

AU - Carugno, Michele

AU - Dalla Valle, Elisabetta

AU - Barretta, Francesco

AU - Cortini, Francesca

AU - Scarpini, Elio

AU - Valentina, Valentina Bollati

AU - Pesatori, Angela Cecilia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Epigenetic mechanisms might be involved in Alzheimer's disease (AD). Genetic polymorphisms in several genes, including APOE (Apolipoprotein E), PSEN1 (Presenilin 1), CR1 (Complement receptor 1), and PICALM (Phosphatidylinositol binding clathrin assembly protein), have been associated to an increased AD risk. However, data regarding methylation of these specific genes are lacking. We evaluated DNA methylation measured by quantitative bisulfite-PCR pyrosequencing in 43 AD patients and 38 healthy subjects (HS). In a multivariate age- and gender-adjusted model, PICALM methylation was decreased in AD compared to HS (mean = 3.54 and 4.63, respectively, p = 0.007). In AD, PICALM methylation level was also positively associated to Mini-Mental Scale Examination (MMSE) score (percent change 3.48%, p = 0.008). Moreover, a negative association between PICALM methylation and age was observed only in HS (percent change - 2.29%, p = 0.002). In conclusion, our data suggest a possible role of PICALM methylation in AD, particularly related to cognitive function. Given the small study sample and the associative nature of our study, further prospective investigations are required to assess the dynamics of DNA methylation in the early stages of AD development.

AB - Epigenetic mechanisms might be involved in Alzheimer's disease (AD). Genetic polymorphisms in several genes, including APOE (Apolipoprotein E), PSEN1 (Presenilin 1), CR1 (Complement receptor 1), and PICALM (Phosphatidylinositol binding clathrin assembly protein), have been associated to an increased AD risk. However, data regarding methylation of these specific genes are lacking. We evaluated DNA methylation measured by quantitative bisulfite-PCR pyrosequencing in 43 AD patients and 38 healthy subjects (HS). In a multivariate age- and gender-adjusted model, PICALM methylation was decreased in AD compared to HS (mean = 3.54 and 4.63, respectively, p = 0.007). In AD, PICALM methylation level was also positively associated to Mini-Mental Scale Examination (MMSE) score (percent change 3.48%, p = 0.008). Moreover, a negative association between PICALM methylation and age was observed only in HS (percent change - 2.29%, p = 0.002). In conclusion, our data suggest a possible role of PICALM methylation in AD, particularly related to cognitive function. Given the small study sample and the associative nature of our study, further prospective investigations are required to assess the dynamics of DNA methylation in the early stages of AD development.

KW - Alzheimer's disease

KW - epigenetics

KW - methylation

KW - Mini-Mental State Examination

KW - PICALM

UR - http://www.scopus.com/inward/record.url?scp=85051870608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051870608&partnerID=8YFLogxK

U2 - 10.3233/JAD-180242

DO - 10.3233/JAD-180242

M3 - Article

VL - 65

SP - 283

EP - 292

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -